Polarean Imaging PLC General Meeting: Change of Venue (4682H)
25 Marzo 2020 - 1:00AM
UK Regulatory
TIDMPOLX
RNS Number : 4682H
Polarean Imaging PLC
25 March 2020
Polarean Imaging Plc
("Polarean" or the "Company")
General Meeting: Change of Venue
Polarean Imaging plc (AIM: POLX), a clinical stage medical
imaging technology company developing a proprietary magnetic
resonance imaging (MRI) drug-device combination, announces that i n
light of the UK Government's latest announcements in response to
the Covid-19 outbreak, it is no longer practical to hold the
forthcoming General Meeting at the Reed Smith LLP London
office.
The General Meeting will still proceed at 2.00pm (BST), or 9am
US local time, on the previously notified date of 1 April 2020 but,
pursuant to Polarean's articles of association, the Board has
determined that it will instead be held at the Company's offices
(2500 Meridian Parkway (Suite 175), Durham, NC 27713, USA) and that
only the number of shareholders required for the General Meeting to
be quorate should physically attend. The Board encourages
shareholders who have not already done so to submit their votes by
proxy rather than attend the General Meeting in person.
The Company will provide a facility for shareholders to join the
General Meeting either online or telephonically and there will be
an opportunity for shareholders to ask questions. In order to
facilitate the process, and so that questions can be fully answered
at the end of the meeting, the Board would request questions to be
submitted in advance, before 5pm (BST) on Monday, 30 March
2020.
To register for dial-in details and to submit any questions
please contact Walbrook PR via email at polarean@walbrookpr.com or
call +44 (0)20 7933 8780.
A letter addressed to the Company's shareholders which provides
additional information regarding the new arrangements for the
General Meeting is now available to download via the Company's
website at:
https://www.polarean-ir.com/content/investors/shareholder-information
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Via Walbrook PR
Officer
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Soltan Tagiev
(Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate
Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7879
741 001
About Polarean's Technology
Polarean's technology produces hyperpolarized inert Xenon gas,
used in conjunction with standard MRI to create high-resolution
three-dimensional functional maps of the human lung. This technique
provides a unique and sensitive way to monitor changes in lung
structure and function; it is currently used in basic and clinical
research to study lung physiology and to monitor the efficacy of
new drugs.
The central equipment required for hyperpolarized gas MRI is a
polarizer. Using circularly polarized laser light, the polarizer
transforms the inert, stable noble gas isotope (129) Xenon into its
hyperpolarized state. This process leaves the gas chemically
unchanged, while only the nucleus is magnetically aligned. The
resulting MRI signal is enhanced by a factor of 100,000, making
direct imaging of gas atoms possible.
About Polarean ( www.polarean.com )
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue-generating, medical drug-device
combination companies operating in the high-resolution medical
imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specializes in the use of hyperpolarized Xenon gas ((129) Xe) as an
imaging agent to visualize ventilation.(129) Xe gas is currently
being studied for visualization of gas exchange regionally in the
smallest airways of the lungs, the tissue barrier between the lung,
and the bloodstream and in the pulmonary vasculature. Xenon gas
exhibits solubility and signal properties that enable it to be
imaged within other tissues and organs.
The Group also develops and manufactures high performance MRI
radiofrequency (RF) coils which are a required component for
imaging (129) Xe in the MRI system. The development of these coils
by the Group facilitates the adoption of the Xenon technology by
providing application-specific RF coils which optimize the imaging
of (129) Xe in MRI equipment for use as a medical diagnostic as
well as a method of monitoring the efficacy of therapeutic
intervention.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOGFFFSIVFISFII
(END) Dow Jones Newswires
March 25, 2020 03:00 ET (07:00 GMT)
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024